Thais S Yokoyama
Overview
Explore the profile of Thais S Yokoyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos-Baldaia R, Wuo-Silva R, Sanabria V, Baldaia M, Yokoyama T, Coppi A, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36830920
The present study aimed to characterize the phenomenon of behavioral sensitization to cocaine and to identify neuroanatomical structures involved in the induction and expression phases of this phenomenon. For this,...
2.
Marinho E, Oliveira-Lima A, Reis H, Santos-Baldaia R, Wuo-Silva R, Hollais A, et al.
Front Pharmacol
. 2023 Feb;
14:1100527.
PMID: 36814501
The endocannabinoid system has been implicated in the neurobiology of opioid use disorder. While the CB1 receptor antagonist rimonabant has been shown to block some of the behavioral effects of...
3.
Henriques G, Anjos-Santos A, Rodrigues I, Nascimento-Rocha V, Reis H, Libarino-Santos M, et al.
Front Pharmacol
. 2021 Oct;
12:739012.
PMID: 34621171
Ibogaine is a psychedelic extracted from the plant , natural from Africa, and has been proposed as a potential treatment for substance use disorders. In animal models, ibogaine reduces ethanol...
4.
Ferreira S, Soares L, Lira C, Yokoyama T, Engi S, Cruz F, et al.
Neurosci Lett
. 2021 Feb;
749:135745.
PMID: 33610663
Ethanol consumption may promote neuroplasticity and alterations in synapses, resulting in modifications in neuronal activity. Here, we treated male Swiss mice with ethanol (2.2 g/kg) or saline once per day...
5.
Reis H, Rodrigues I, Anjos-Santos A, Libarino-Santos M, Serra Y, Cata-Preta E, et al.
Psychopharmacology (Berl)
. 2020 Jul;
237(11):3269-3281.
PMID: 32676773
Rationale: Accumulating evidence suggests that ayahuasca, a hallucinogenic beverage used in traditional Amazonian communities for ritualistic and curative purposes, has been associated with reduced rates of substance use disorders. However,...
6.
Wuo-Silva R, Fukushiro-Lopes D, Fialho B, Hollais A, Santos-Baldaia R, Marinho E, et al.
Front Pharmacol
. 2019 Mar;
10:211.
PMID: 30914950
Studies on the abuse potential of modafinil, a psychostimulant-like drug used to treat narcolepsy, are still controversial. While some studies claim no potential for abuse, increasing evidence suggests that modafinil...
7.
Marinho E, Oliveira-Lima A, Yokoyama T, Santos-Baldaia R, Ribeiro L, Baldaia M, et al.
Pharmacol Biochem Behav
. 2017 Apr;
156:16-23.
PMID: 28366798
CB1 receptor antagonists have been shown to prevent acute and long-term behavioral effects of cocaine. Here we evaluate the effectiveness of the CB1 receptor antagonist rimonabant to modify sensitized responses...
8.
Wuo-Silva R, Fukushiro D, Hollais A, Santos-Baldaia R, Mari-Kawamoto E, Berro L, et al.
Front Pharmacol
. 2016 Nov;
7:420.
PMID: 27872594
There is substantial controversy about the addictive potential of modafinil, a wake-promoting drug used to treat narcolepsy, proposed as pharmacotherapy for cocaine abuse, and used indiscriminately by healthy individuals due...
9.
Marinho E, Oliveira-Lima A, Santos R, Hollais A, Baldaia M, Wuo-Silva R, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2014 Dec;
58:22-31.
PMID: 25496830
Rationale: The endocannabinoid system has been implicated in the neurobiological mechanism underlying drug addiction, especially the primary rewarding dopamine-dependent processes. Therefore, endocannabinoid receptor antagonists, such as the CB1 cannabinoid antagonist...